# A Fixed Dose, Dose Response Study for Ropinirole Prolonged Release in Patients With Early Stage Parkinson's Disease

> **NCT01485172** · PHASE4 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 186 (actual)

## Conditions studied

- Parkinson Disease

## Interventions

- **DRUG:** ropinirole monotherapy
- **DRUG:** placebo monotherapy

## Key facts

- **NCT ID:** NCT01485172
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-01-31
- **Primary completion:** 2014-04-30
- **Final completion:** 2014-04-30
- **Target enrollment:** 186 (ACTUAL)
- **Last updated:** 2018-06-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01485172

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01485172, "A Fixed Dose, Dose Response Study for Ropinirole Prolonged Release in Patients With Early Stage Parkinson's Disease". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT01485172. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*